Regeneron Pharmaceuticals, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Leonard S. Schleifer
- Full Time Employees
- 15,158
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 777 Old Saw Mill River Road Tarrytown NY United States of America 10591-6707
- IPO Date
- Apr 2, 1991
- CIK
- 0000872589
- Website
- regeneron.com
- Similar Companies
- Business
- Regeneron Pharmaceuticals, Inc. (REGN) is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases including eye disorders, allergic and inflammatory conditions, cancer, cardiovascular and metabolic diseases, neurological disorders, hematologic conditions, infectious diseases and rare diseases. Founded in 1988 and headquartered in Tarrytown, New York, the company operates globally with facilities in the United States and clinical trials underway in more than 50 countries; it employs proprietary technologies such as VelociSuite for fully human antibodies and bispecifics, Trap fusion proteins and the Regeneron Genetics Center for data-powered insights. Its marketed products include EYLEA (aflibercept) for retinal diseases such as wet age-related macular degeneration, diabetic macular edema and macular edema following retinal vein occlusion; Dupixent (dupilumab, in collaboration with Sanofi) for atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps and other allergic conditions; Praluent (alirocumab) for hypercholesterolemia; Kevzara (sarilumab, with Sanofi) for rheumatoid arthritis; Libtayo (cemiplimab) for cutaneous squamous cell carcinoma and other cancers; ARCALYST (rilonacept) for autoinflammatory diseases; ZALTRAP (ziv-aflibercept) for metastatic colorectal cancer; Inmazeb for Ebola virus infection; Veopoz (pozelimab) for CHAPLE disease; as well as investigational candidates across oncology, hematology, immunology and neurology. In recent developments, Regeneron formed Regeneron Cell Medicines in 2024 through an agreement acquiring 2seventy bio's immune cell therapy pipeline, discovery and manufacturing capabilities along with approximately 150 employees in Cambridge, Massachusetts, and Seattle, Washington; announced a $3 billion-plus, 10-year manufacturing agreement with FUJIFILM Diosynth Biotechnologies in 2025 to nearly double U.S. large-scale capacity at the Holly Springs, North Carolina facility; launched a $500 million venture capital fund in 2024 focused on biotech investments; entered a collaboration with Tessera Therapeutics in December 2025 to co-develop TSRA-196, a gene-editing therapy for alpha-1 antitrypsin deficiency, with Tessera receiving $150 million upfront and up to $125 million in milestones; secured FDA approval for EYLEA HD in retinal vein occlusion with expanded dosing in 2025; and won a $406.8 million antitrust judgment against Amgen in May 2025 over Praluent market exclusion. The company continues to advance its pipeline with positive late-stage data in immunology, allergy, neurology and rare diseases, while expanding R&D investments and domestic manufacturing to support growth.
Why Regeneron (REGN) is a Top Momentum Stock for the Long-Term
Wall Street Thinks This High-Flying Biotech Stock Can Soar Another 57%
FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports
Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities
This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested
From Vaccines to Therapeutics; How Biotech Is Addressing the Ebola Outbreak
Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast
Is AbbVie a Buy After Its Purchase of Apogee?
Regeneron's Applications for gMG Drug Accepted by FDA and EMA
2 Underrated Weight Loss Stocks to Buy and Hold
Breakfast News: AbbVie's $11 Billion Pounce
Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)
This Stock Is Up 58% This Year. Is It too Late to Buy?
Here's Why Regeneron (REGN) is a Strong Value Stock
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
REGN Investors Have Opportunity to Join Regeneron Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
REGN Investors Have Opportunity to Join Regeneron Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Regeneron: 'Buy' Revenue Growth And Two Extensive Drug Development Opportunities